再激活前普萘洛尔治疗减少PTSD症状:一项随机对照试验
该6周双盲安慰剂对照随机临床试验纳入60名长期PTSD成人,每周在短暂创伤记忆再激活前90分钟给予普萘洛尔或安慰剂,共6次。意向性分析显示,普萘洛尔组CAPS评分组间差11.50,PCL-S每周多降2.43分、总差14.58分,均显著优于安慰剂。结论认为再激活前普萘洛尔可能是PTSD的新型有效治疗,需在多种创伤人群中长期随访重复验证。
要点
- 再激活前90分钟给予普萘洛尔,每周1次共6周,可显著降低PTSD症状。
- CAPS组间差11.50,PCL-S总差14.58分,均优于安慰剂。
- 需在多种创伤人群中长期随访重复验证。
核心结论
- 再激活前普萘洛尔这一基于再巩固理论的方案,似乎是PTSD的一种新型有效治疗。
- 作者要求在不同创伤人群中进行长期随访的重复研究。
研究设计与样本
- 6周双盲、安慰剂对照、随机临床试验,纳入60名诊断为长期PTSD的成人。
- 普萘洛尔或安慰剂在每周一次、连续6周的短暂记忆再激活 session 前90分钟给药。
- 主要分析为意向性治疗分析,评估CAPS与PCL-S。
主要发现
- 治疗后CAPS评分经协方差分析调整基线后,组间估计差值为11.50,具统计学显著性。
- CAPS组内前后效应量Cohen's d:普萘洛尔1.76,安慰剂1.25。
- PCL-S混合线性模型时间×组交互估计每周平均多降2.43分,总显著差异比安慰剂多14.58分。
- PCL-S组内前后效应量:普萘洛尔2.74,安慰剂0.55。
- 符合方案分析对两项结局均得到相似的显著结果。
临床怎么用
- 对于长期PTSD成人,可考虑在短暂创伤记忆再激活前90分钟给予普萘洛尔,每周1次共6周。
- 疗效评估可结合临床医生评定的CAPS与患者自评的PCL-S。
局限性
- 需在不同创伤人群中进行重复研究并长期随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors assessed the efficacy of trauma memory reactivation performed under the influence of propranolol, a noradrenergic beta-receptor blocker, as a putative reconsolidation blocker, in reducing symptoms of posttraumatic stress disorder (PTSD). METHOD: This was a 6-week, double-blind, placebo-controlled, randomized clinical trial in 60 adults diagnosed with long-standing PTSD. Propranolol or placebo was administered 90 minutes before a brief memory reactivation session, once a week for 6 consecutive weeks. The hypothesis predicted a significant treatment effect of trauma reactivation with propranolol compared with trauma reactivation with placebo in reducing PTSD symptoms on both the Clinician-Administered PTSD Scale (CAPS) and the patient-rated PTSD Checklist-Specific (PCL-S) in an intention-to-treat analysis. RESULTS: The estimated group difference in posttreatment CAPS score, adjusted for pretreatment values (analysis of covariance), was a statistically significant 11.50. The within-group pre- to posttreatment effect sizes (Cohen's d) were 1.76 for propranolol and 1.25 for placebo. For the PCL-S, the mixed linear model's estimated time-by-group interaction yielded an average decrease of 2.43 points per week, for a total significant difference of 14.58 points above that of placebo. The pre- to posttreatment effect sizes were 2.74 for propranolol and 0.55 for placebo. Per protocol analyses for both outcomes yielded similar significant results. CONCLUSIONS: Pre-reactivation propranolol, a treatment protocol suggested by reconsolidation theory, appears to be a novel and efficacious treatment for PTSD. Replication studies using a long-term follow-up in various trauma populations are required.
引用
- Brunet A, Saumier D, Liu A, et al. Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial. Am J Psychiatry. 2018. PMID: 29325446. doi:10.1176/appi.ajp.2017.17050481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。